IPO Pro - "The Ultimate Resource for IPOs"
Don't risk buying another IPO without IPO Pro.
Get your FREE TRIAL now.
Preclinical biotech developing T cell therapies for solid tumors.
Industry: Health Care
Latest Trade: $2.46 0.00 (0.0%)
First Day Return: -0.6%
Return from IPO: -85.5%
Industry: Health Care
IPO Data | |
---|---|
IPO File Date | 05/25/2021 |
Offer Price | $17.00 |
Price Range $16.00 - $18.00 | |
Offer Shares (mm) | 25.0 |
Deal Size ($mm) | $425 |
Lock-Up Date | IPO Pro Only |
Street Research | IPO Pro Only |
IPO Data | |
---|---|
IPO Date | 06/16/2021 |
Offer Price | $17.00 |
Price Range $16.00 - $18.00 | |
Offer Shares (mm) | 25.0 |
Deal Size ($mm) | $425 |
Lock-Up Date | IPO Pro Only |
Street Research | IPO Pro Only |
Underwriters |
---|
Goldman Sachs |
BofA Securities |
more |
Company Data | |
---|---|
Headquarters | South San Francisco, CA, United States |
Founded | 2018 |
Employees | 190 |
Website www.lyell.com |